- Home
- LDWY vs ALBT Comparison
LDWY vs ALBT Comparison
Compare LDWY & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- ALBT
- Stock Information
- Founded
- LDWY 1990
- ALBT 2014
- Country
- LDWY United States
- ALBT United States
- Employees
- LDWY N/A
- ALBT N/A
- Industry
- LDWY Advertising
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDWY Consumer Discretionary
- ALBT Health Care
- Exchange
- LDWY Nasdaq
- ALBT Nasdaq
- Market Cap
- LDWY 9.2M
- ALBT 7.4M
- IPO Year
- LDWY 1991
- ALBT N/A
- Fundamental
- Price
- LDWY $4.95
- ALBT $2.16
- Analyst Decision
- LDWY
- ALBT
- Analyst Count
- LDWY 0
- ALBT 0
- Target Price
- LDWY N/A
- ALBT N/A
- AVG Volume (30 Days)
- LDWY 4.6K
- ALBT 1.5M
- Earning Date
- LDWY 08-18-2025
- ALBT 08-18-2025
- Dividend Yield
- LDWY N/A
- ALBT N/A
- EPS Growth
- LDWY N/A
- ALBT N/A
- EPS
- LDWY N/A
- ALBT N/A
- Revenue
- LDWY $42,183,000.00
- ALBT $807,235.00
- Revenue This Year
- LDWY N/A
- ALBT N/A
- Revenue Next Year
- LDWY N/A
- ALBT N/A
- P/E Ratio
- LDWY N/A
- ALBT N/A
- Revenue Growth
- LDWY 425.12
- ALBT N/A
- 52 Week Low
- LDWY $3.02
- ALBT $1.87
- 52 Week High
- LDWY $5.60
- ALBT $12.60
- Technical
- Relative Strength Index (RSI)
- LDWY 49.85
- ALBT 43.99
- Support Level
- LDWY $4.95
- ALBT $2.15
- Resistance Level
- LDWY $5.06
- ALBT $4.74
- Average True Range (ATR)
- LDWY 0.16
- ALBT 0.35
- MACD
- LDWY -0.01
- ALBT 0.02
- Stochastic Oscillator
- LDWY 59.11
- ALBT 11.34
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.